BPC-157 vs Ziconotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Body Protection Compound-157, Pentadecapeptide BPC 157
A synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
Also: Prialt, SNX-111
A synthetic cone snail venom peptide for severe chronic pain. The first intrathecal non-opioid analgesic FDA approved.
Key Comparison Insights
- Ziconotide is FDA approved, while BPC-157 remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Ziconotide has stronger research evidence (FDA Approved) compared to BPC-157 (Animal Studies).
Detailed Comparison
| Attribute | BPC-157 | Ziconotide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | BPC-157 modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), and upregulates growth hormone receptors. It also interacts with the dopaminergic system and has been shown to accelerate tendon-to-bone healing by promoting collagen synthesis. | Ziconotide blocks N-type voltage-gated calcium channels (Cav2.2) in the spinal cord. This prevents neurotransmitter release from pain-signaling neurons, providing analgesia without opioid receptor involvement. |
| Common Dosing | 250-500 mcg twice daily 1-2x daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection near injury site, or systemic | Intrathecal infusion only |
| Typical Duration | 4-12 weeks in most research protocols | Chronic use via intrathecal pump |
| Best Time to Take | Morning and evening (or near injury site timing) | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract. Only 3 small human pilot studies exist (fewer than 30 total subjects). FDA placed BPC-157 in Category 2 in September 2023, meaning it cannot be used in compounded medications due to insufficient safety data. | Effective for severe chronic pain refractory to other treatments. Studies show significant pain reduction without tolerance development. Complex delivery limits use to specialized pain centers. |
Frequently Asked Questions: BPC-157 vs Ziconotide
What is the difference between BPC-157 and Ziconotide?
BPC-157 is a healing peptide that a synthetic peptide derived from a protein found in human gastric juice. known for its remarkable tissue healing properties across multiple body systems. fda classified as category 2 in 2023, restricting compounding. Ziconotide is a healing peptide that a synthetic cone snail venom peptide for severe chronic pain. the first intrathecal non-opioid analgesic fda approved. The main differences lie in their mechanisms of action and clinical applications.
Which is better, BPC-157 or Ziconotide?
Neither is universally "better" - the choice depends on your specific goals. BPC-157 is typically used for healing purposes, while Ziconotide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can BPC-157 and Ziconotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using BPC-157 and Ziconotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of BPC-157 and Ziconotide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.